Cosmetic cross-reference Noindex: medium evidence

Isalon

CAS 5579-81-7

Isalon (CAS 5579-81-7) is a pharmaceutical compound with 0 bioactivity targets and 7 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
7
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EPA DSSTox

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Isalon
CAS Number
5579-81-7
Molecular Formula
C4H6N4O3.Al.2H2O
InChIKey
JBSKYLXIYKLOLP-UHFFFAOYSA-K
Source Match
EPA DSSTox
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE DSSTox identifiers DTXSID8057774

Cross-Reference to Chemicals

Same-CAS substance identity is available in the industrial chemicals vertical.

Isalon is linked to DTXSID8057774 in DSSTox identifiers.

View industrial chemical data →
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Isalon used for in pharmaceutical contexts?

Isalon (CAS 5579-81-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Isalon?

Isalon has 7 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Asthma, Decreased appetite, Drug hypersensitivity, Matrix metalloproteinase-3 increased, Mental fatigue. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Isalon also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Aldioxa with EU status "permitted".

What clinical phase is Isalon in?

No phase 1-4 clinical development badge is rendered for Isalon because the matched compound identifier rows do not contain a max-phase value.